This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on VKTX's pipeline updates when it reports first-quarter earnings.
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
by Zacks Equity Research
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. ARGX: Which Stock Is the Better Value Option?
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
by Zacks Equity Research
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
by Zacks Equity Research
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
by Zacks Equity Research
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
by Zacks Equity Research
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
by Zacks Equity Research
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
CORT's Q4 Earnings and Revenues Fall Short of Estimates
by Zacks Equity Research
Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
by Zacks Equity Research
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
by Zacks Equity Research
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Novavax to Report Q4 Earnings: Here's What You Can Expect
by Zacks Equity Research
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.